Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

11.69USD
23 Oct 2018
Change (% chg)

$-0.30 (-2.50%)
Prev Close
$11.99
Open
$11.69
Day's High
$11.69
Day's Low
$11.69
Volume
4,787
Avg. Vol
229,982
52-wk High
$21.69
52-wk Low
$9.00

Chart for

About

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor... (more)

Overall

Beta: 3.75
Market Cap(Mil.): $941.76
Shares Outstanding(Mil.): 60.56
Dividend: --
Yield (%): --

Financials

  KPTI.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -2.83 -- --
ROI: -73.04 1.96 12.83
ROE: -74.59 1.12 14.95

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

May 10 2018

BRIEF-Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln

* KARYOPHARM THERAPEUTICS INC SAYS OFFERING SHARES OF CO'S COMMON STOCK WITH AN AGGREGATE OFFERING PRICE OF $125 MILLION - SEC FILING Source text : (https://bit.ly/2w3kEIH) Further company coverage:

May 01 2018

BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock

* KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

May 01 2018

BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma

* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

Apr 30 2018

Earnings vs. Estimates